Table 1.

The basic information of 14 eligible studies in this meta-analysis.

First author	Literature years	Indications	Age of AZM experimental group (yr)	Administration mode of AZM experimental group	Treatment methods of control group
Goyal V.[7]	2018	Acute exacerbation of bronchiectasis	4~9	Oral administration	Other treatment
Kneyber M.[8]	2012	Lower respiratory diseases	0.3~6	Intravenous administration	Other treatment
Vikas G.[9]	2018	Bronchiectasis	1~17	Sequential therapy	Other treatment
Valery PC[10]	2013	Bronchiectasis	0.6~8	Oral administration	Other treatment
Postma D.F.[11]	2010	Acquired pneumonia	1~7	Intravenous administration	Erythromycin
Hendricks[12]	2016	Mycoplasma pneumonia	3~12	Sequential therapy	Other treatment
Wilms E.B.[13]	2012	Cystic fibrosis	0.6~12	Intravenous administration	Other treatment
Bauer K.A.[14]	2011	Other symptoms	1~10.5	Intravenous administration	Erythromycin
Small S.M.[15]	2018	Acquired pneumonia	1~10	Sequential therapy	Erythromycin
To K.K.[16]	2010	Mycoplasma pneumonia	2~10	Sequential therapy	Other treatment
Yang D.[17]	2018	Mycoplasma pneumonia	4~13	Oral administration	Erythromycin
Lu M.P.[18]	2013	Mycoplasma pneumonia	0.6~12	Intravenous drip	Erythromycin
Han R.[19]	2020	Mycoplasma pneumonia	4~9	Sequential therapy	Erythromycin
Wang J.[20]	2018	Mycoplasma pneumonia	0.3~12	Oral administration	Other treatment

Other treatment refers to amoxicillin, cefuroxime, and other antibiotics rather than macrolides.